We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ip Group Plc | LSE:IPO | London | Ordinary Share | GB00B128J450 | ORD 2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.80 | 1.68% | 48.30 | 47.95 | 48.00 | 48.70 | 47.50 | 47.50 | 6,255,691 | 16:35:10 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | -140.1M | -174.4M | -0.1682 | -2.85 | 497.2M |
From Apr 2019 to Apr 2024
By Adam Clark
IP Group PLC (IPO.LN) said on Wednesday that its investment company Microbiotica Ltd. has entered a strategic collaboration with Roche Holding AG's (ROG.EB) Genentech, in a deal worth up to $534 million.
IP Group holds a 33% beneficial stake in Microbiotica. IP said Microbiotica will use its microbiome platform to analyze patient samples from Genentech's clinical trials of inflammatory bowel disease treatments.
Microbiotica will receive an undisclosed upfront payment, milestone payments, and is eligible to receive royalties on certain product sales, said IP Group.
At 0839 GMT, shares in IP Group were up 4.20 pence, or 3%, at 142.80 pence.
Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones
(END) Dow Jones Newswires
June 06, 2018 05:00 ET (09:00 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Ip Chart |
1 Month Ip Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
